Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

M2727

Sigma-Aldrich

Mexiletine hydrochloride

≥98% (GC), powder, sodium channel blocker

Synonym(s):

1-(2,6-Dimethylphenoxy)-2-propanamine hydrochloride, 1-(2,6-Xylyloxy)-2-aminopropane hydrochloride

Sign Into View Organizational & Contract Pricing

Select a Size

25 G
$130.00
100 G
$407.70

$130.00


Available to ship onApril 25, 2025Details


Request a Bulk Order

Select a Size

Change View
25 G
$130.00
100 G
$407.70

About This Item

Empirical Formula (Hill Notation):
C11H17NO · HCl
CAS Number:
Molecular Weight:
215.72
EC Number:
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

$130.00


Available to ship onApril 25, 2025Details


Request a Bulk Order

Product Name

Mexiletine hydrochloride, powder

assay

≥98% (GC)

Quality Level

form

powder

color

white to off-white

solubility

methanol: 50 mg/mL

originator

Boehringer Ingelheim

storage temp.

2-8°C

SMILES string

Cl[H].CC(N)COc1c(C)cccc1C

InChI

1S/C11H17NO.ClH/c1-8-5-4-6-9(2)11(8)13-7-10(3)12;/h4-6,10H,7,12H2,1-3H3;1H

InChI key

NFEIBWMZVIVJLQ-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

Mexiletine is a class I B antiarrhythmic[1] and an analog of lidocaine.[2] It has shelf life of 10-12 hours and is metabolized in liver and eliminated post reduction, oxidation deamination or conjugation.[3]

Application

Mexiletine hydrochloride has been used as a sodium channel blocker:
  • expressed in chinese hamster ovary cells[4]
  • in human embryonic kidney (HEK) cells for whole cell patch-clamp studies[5]
  • electrophysiology studies in HEK cells expressing Nav1.7 protein[6]

Biochem/physiol Actions

Mexiletine is a potent sodium channel blocker.[1] It is a cardiac antiarrhythmic and is used as an adjuvant in headache and neuropathic pain[2] Mexiletine is used for treating myotonia in sodium channelopathies[7] and reduces the cardiac action potential depolarization but shows no impact on atrial refractoriness.[1] Its inhibitory effect on sodium channels is effective in treating potassium aggravated myotonia.[7]

Features and Benefits

This compound was developed by Boehringer Ingelheim. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Mexiletine
Monk, Jon P and Brogden, Rex N
Drugs, 40(3), 374-411 (1990)
Arnold E Pfahnl et al.
Heart rhythm, 4(1), 46-53 (2007-01-03)
Brugada and long QT type 3 syndromes are linked to sodium channel mutations and clinically cause arrhythmias that lead to sudden death. We have identified a novel threonine-to-isoleucine missense mutation at position 353 (T353I) adjacent to the pore-lining region of
Adam Romman et al.
Pain physician, 21(5), E573-E579 (2018-10-05)
Intravenous lidocaine has multiple applications in the management of acute and chronic pain. Mexiletine, an oral lidocaine analogue, has been used in a number of chronic pain conditions although its use is not well characterized. To report our experience using
K Mori et al.
Naunyn-Schmiedeberg's archives of pharmacology, 358(6), 641-648 (1999-01-08)
Recently we have reported that class III antiarrhythmic drugs including amiodarone inhibit the Na+-activated K+ (KNa) channels in isolated cardiac cells. In this study effects of antiarrhythmic drugs having class I and/or IV properties on the single KNa channel current
E L Logigian et al.
Neurology, 74(18), 1441-1448 (2010-05-05)
To determine if mexiletine is safe and effective in reducing myotonia in myotonic dystrophy type 1 (DM1). Myotonia is an early, prominent symptom in DM1 and contributes to decreased dexterity, gait instability, difficulty with speech/swallowing, and muscle pain. A few

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service